A 3-month MOBILE analysis finds CGM lowers HbA1c more than fingerstick monitoring and reduces hypoglycaemia in basal-insulin-treated type 2 diabetes, with benefits within a week. PICO summary and commentary.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A pilot RCT finds a culturally and linguistically tailored programme improves self-efficacy, diabetes distress, and diet adherence in Chinese Americans with type 2 diabetes. PICO summary and commentary.
📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context This landmark…
Summary: In adults with type 2 diabetes in resource-limited, peri-urban and rural primary health center (PHC) areas in India, ASHA-led…
Clinical Context Sleep disturbances and type 2 diabetes share a bidirectional relationship that is often underappreciated in clinical practice. Approximately…
An RCT finds combined aerobic and resistance training improves modelled insulin secretion and glucose effectiveness more than either alone in men with type 2 diabetes. PICO summary and commentary.
Summary: In adults diagnosed with type 2 diabetes mellitus enrolled in a randomized controlled trial comparing exercise modalities, combined aerobic…
A 12-month RCT finds daily curcumin reduces liver fat, stiffness, and HbA1c and improves inflammatory and antioxidant markers in obese type 2 diabetes with fatty liver. PICO summary and commentary.
A crossover RCT finds a specific Bifidobacterium animalis probiotic blunts the rise in glucose and insulin resistance and raises immunoglobulins in type 2 diabetes, with modest adjunctive benefit. PICO summary and commentary.
A 2-year pragmatic open-label trial finds once-weekly semaglutide modestly outperforms physician-chosen alternatives on HbA1c targets, with a year-1 weight advantage that fades by year 2. PICO summary and commentary.